Načítá se...
Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
BACKGROUND: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody...
Uloženo v:
| Vydáno v: | Iran Biomed J |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Pasteur Institute
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889503/ https://ncbi.nlm.nih.gov/pubmed/28992681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/ibj.22.3.180 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|